J.A. Lieberman

Stanley Medical Research Institute — United States

Medicine · Health Sciences

31h-index6.8kcitations82works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(37), Neurotransmitter Receptor Influence on Behavior(11), Treatment of Major Depression(10), Functional Brain Connectivity Studies(9), Diet and metabolism studies(8)

Publications82 total

The Underuse of Clozapine and Long-Acting Injectable Antipsychotics
Psychiatric Services·2024· 9 cited
A comprehensive analysis of 22q11 gene expression in the developing and adult brain
UNC Libraries·2020· 5 citedOpen Access
Medicine and the Mind
New England Journal of Medicine·2020· 2 cited
The role of the ITIH3 rs2535629 variant in antipsychotic response
Schizophrenia Research·2016· 28 cited
Early Psychosis Intervention Services: A Work in Progress
Schizophrenia Bulletin·2014· 7 citedOpen Access
P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies
European Neuropsychopharmacology·2013
P.3.e.017 Effects of alpha7 nicotinic receptor agonist TC-5619 in cognitive dysfunction in schizophrenia
European Neuropsychopharmacology·2011· 3 cited
P.3.c.065 Comparison of multifactor dimensionality reduction (MDR) and neural network analysis: serotonergic system genes and antipsychotic response
European Neuropsychopharmacology·2010
P.1.a.018 Admixture analysis in pharmacogenetics: serotonergic system genes and antipsychotic response
European Neuropsychopharmacology·2009
Concurrent Measurement of "Real-World" Stress and Arousal in Individuals With Psychosis: Assessing the Feasibility and Validity of a Novel Methodology
Schizophrenia Bulletin·2009· 67 citedOpen Access
P.1.a.002 Glial cell-derived neurotrophic family (GFR) alpha 1 receptor polymorphisms and weight change during clozapine treatment
European Neuropsychopharmacology·2008
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Schizophrenia Bulletin·2007· 169 citedOpen Access
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
PubMed·2006· 19 cited
Limited influence of olanzapine on adult forebrain neural precursors in vitro
Neuroscience·2006· 16 cited
List of Contributors, Part 2
Techniques in the behavioral and neural sciences·2005
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
Molecular Psychiatry·2004· 971 cited
Deficits in mismatch negativity in schizophrenia: Predictor of outcome or result of illness progression?
Schizophrenia Research·2003· 2 cited
Decreased PAR-4 in the temporal cortex of subjects with schizophrenia
Schizophrenia Research·2003
Computerized neurocognitive assessment: Clinical trials and FMRI applications
Schizophrenia Research·2003
Acute Pharmacological Treatment of Schizophrenia
2003· 12 cited
page 1 of 5Next →

Frequent Co-authors

John M. Kane(14), Margaret G. Woerner(7), Miranda Chakos(6), Robert M. Bilder(6), Seiya Miyamoto(3), G E Duncan(3), Michael Borenstein(3), A. Koreen(3), Simcha Pollack(3), Allan Z. Safferman(3), H Novacenko(3), Manzar Ashtari(3), Gustav Degreef(3), Thomas M. Maynard(2), José Alvir(2), Bruce L. Saltz(2), James T. Wegner(2), Richard B. Mailman(2), Robert W. Buchanan(2), Heidi Lee(2)